Department of Biology, Mashhad Branch, Islamic Azad University, P.O. Box: 91871-47578, Mashhad, Iran.
Department of Biochemistry, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.
Mol Biol Rep. 2022 Jul;49(7):6975-6985. doi: 10.1007/s11033-022-07465-3. Epub 2022 May 5.
Biomarkers, such as microRNAs, are helpful in diagnosing colorectal cancer, regulating disease progression, predicting disease recurrence, and determining therapy success. This research aimed to look at the clinicopathological characteristics of serum miRNA-203a-3p expression in colorectal cancer patients.
This case-control study was conducted on 43 patients with colorectal cancer and 43 healthy individuals. After RNA extraction, cDNA was synthesized. The expression of miR-203a-3p was measured using RT-qPCR. Demographic and histochemical data were extracted from patient documents. SPSS and GraphPad Prism software were used to analyze the data. The expression of miR-203a-3p in CRC patients was 2.39 times lower than in the control group (p < 0.0001). The miR-203a-3p expression was significantly lower in the CRC tumor stages, tumor grades, and lymph node metastasis compared to the control group (p < 0.0001 each). The ROC curves showed that the AUC was 0.73, and the best cut-point based on the Youden index was 0.3954, 0.7105, 0.5087, and 0.4868 for detecting colorectal cancer (p = 0.0002), tumor grade (p = 0.006), tumor stage (p = 0.001), and lymph node metastasis (p = 0.0011) compared to the control group, respectively. The binary logistic regression analysis was performed on the correlation between BMI, smoking, and cancer inheritance with miR-203a-3p in cancer and control groups.
This study's findings revealed that serum miR-203a-3p is a fair non-invasive molecular biomarker for diagnosing and progressing tumor grade, tumor stage, and lymph node metastasis in colorectal cancer. However, further research with higher statistical numbers is needed to strengthen the correlation and be used for diagnostic applications.
生物标志物，如 microRNAs，有助于诊断结直肠癌、调节疾病进展、预测疾病复发和确定治疗成功。本研究旨在观察结直肠癌患者血清 miRNA-203a-3p 表达的临床病理特征。
本病例对照研究纳入 43 例结直肠癌患者和 43 例健康个体。提取 RNA 后，合成 cDNA。使用 RT-qPCR 测量 miR-203a-3p 的表达。从患者病历中提取人口统计学和组织化学数据。使用 SPSS 和 GraphPad Prism 软件分析数据。CRC 患者的 miR-203a-3p 表达水平比对照组低 2.39 倍（p<0.0001）。miR-203a-3p 的表达在 CRC 肿瘤分期、肿瘤分级和淋巴结转移中均显著低于对照组（p<0.0001 各）。ROC 曲线显示 AUC 为 0.73，根据 Youden 指数得出的最佳截断值分别为 0.3954、0.7105、0.5087 和 0.4868，用于检测结直肠癌（p=0.0002）、肿瘤分级（p=0.006）、肿瘤分期（p=0.001）和淋巴结转移（p=0.0011），与对照组相比。对癌症和对照组中 BMI、吸烟和癌症遗传与 miR-203a-3p 之间的相关性进行二元逻辑回归分析。
本研究结果表明，血清 miR-203a-3p 是一种公平的非侵入性分子生物标志物，可用于诊断和进展肿瘤分级、肿瘤分期和结直肠癌的淋巴结转移。然而，需要进行具有更高统计数量的进一步研究，以加强相关性并用于诊断应用。
